Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs

Psychiatr Serv. 2003 Oct;54(10):1343-4,1349. doi: 10.1176/appi.ps.54.10.1343.
No abstract available

MeSH terms

  • Cost Savings
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / economics*
  • Drug Costs / statistics & numerical data*
  • Drugs, Generic / economics*
  • Drugs, Generic / therapeutic use
  • Fluoxetine / economics
  • Fluoxetine / therapeutic use
  • Health Maintenance Organizations / economics*
  • Humans
  • Insurance, Pharmaceutical Services / economics*
  • Managed Care Programs / economics*
  • Selective Serotonin Reuptake Inhibitors / economics*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • United States

Substances

  • Drugs, Generic
  • Serotonin Uptake Inhibitors
  • Fluoxetine